Gold Prices Hit Record High Above $5,500 as Iran Strike Fears Fuel Safe-Haven Demand 
Bank of Canada Holds Interest Rate at 2.25% Amid Trade and Global Uncertainty 
Oil Prices Surge Toward Biggest Monthly Gains in Years Amid Middle East Tensions 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
U.S. Eases Venezuela Oil Sanctions to Boost American Investment After Maduro Ouster 
The Maire - EuroChem Case: Three Lessons for Global Business 
Starmer’s China Visit Signals New Era in UK–China Economic Relations 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
U.S. and El Salvador Sign Landmark Critical Minerals Agreement to Boost Investment and Trade 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
UK Vehicle Production Falls Sharply in 2025 Amid Cyberattack, Tariffs, and Industry Restructuring 
Indonesian Stocks Plunge as MSCI Downgrade Risk Sparks Investor Exodus 
Asian Currencies Slip as Dollar Rebounds Ahead of Fed Rate Decision 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
Namyang Dairy Product recently lost two of its leaders - chairman Hong Won Sik and CEO Lee Kwang Bum this week. The two decided to leave over the controversies created by the company’s claim about the effectiveness of its Bulgaris yogurt in fighting COVID-19 symptoms.
The controversy that led to Namyang’s heads exit
Chairman Hong Won Sik stepped down on Tuesday, May 4, and he announced his departure through a press conference. CEO Lee Kwang Bum also left his job on Monday, and their exit came two days after Namyang Dairy’s offices were raided by the authorities as it investigates the COVID-19 false claims.
The two resigned three weeks after the company held a symposium and announced that its Bulgaris yogurt effectively lowers the chance of contracting COVID-19 by at least 77%. However, the South Korean Ministry of Food and Drug Safety called out Namyang for such doubtful claims and immediately launched an investigation.
The public reportedly flocked to grocery stores to buy Namyang’s Bulgaris yogurts, and the company experienced a surge in its shares. This is another reason why a probe has been launched.
New scandal besetting the dairy company
Now, while the yogurt controversy is not yet over, The Korea Times reported that Namyang is facing a new issue. This time it has something to do with a patent infringement violation.
The outlet reported that Namyang’s Inner Care yogurt drink comes with a supplement pill. This is placed in the cap so it can easily be taken when drinking the yogurt. However, the company’s rival, Korea Yakult, that sells MPRO3, which is a probiotics beverage, claimed that the yogurt and pill combination was imitated by Namyang from them.
MPRO3 also comes with a supplement, and Yakult Korea is claiming that they are the originator of this product that was first launched in 2019. On the other hand, Namyang’s Inner Care was only released in February.
With the identical special features between Inner Care and MPRO3, Natural Way, which has the patent rights over Yakult Korea’s design of placing the pill inside the bottle caps, filed a patent lawsuit against Namyang. It was revealed that the filing was done last month.
